Study Results: The PIVOT-PO trial demonstrated that oral tebipenem HBr is non-inferior to intravenous imipenem-cilastatin for treating complicated urinary tract infections (cUTIs), achieving a 58.5% success rate compared to 60.2% for the intravenous option.
Regulatory Plans: Spero Therapeutics and GSK plan to submit data to regulatory authorities in Q4 2025, aiming for tebipenem HBr to become the first oral carbapenem antibiotic approved in the U.S. for cUTIs.
Health Impact: Complicated UTIs, often caused by multidrug-resistant pathogens, pose significant health risks and economic burdens, with millions of cases treated annually in the U.S. and associated healthcare costs exceeding $6 billion.
Future Implications: The introduction of an effective oral treatment option like tebipenem HBr could alleviate the reliance on intravenous antibiotics, improving patient care and addressing the challenges of antibiotic resistance.
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 48.650
Low
20.15
Averages
38.72
High
55.60
Current: 48.650
Low
20.15
Averages
38.72
High
55.60
Clear Street
Buy
to
Hold
downgrade
$60 -> $58
2026-01-20
New
Reason
Clear Street
Price Target
$60 -> $58
AI Analysis
2026-01-20
New
downgrade
Buy
to
Hold
Reason
Clear Street downgraded Rapt Therapeutics (RAPT) to Hold from Buy with a price target of $58, down from $60, after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash. Clear Street cites the deal terms for the downgrade.
Piper Sandler
Overweight -> Neutral
downgrade
$95 -> $58
2026-01-20
New
Reason
Piper Sandler
Price Target
$95 -> $58
2026-01-20
New
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Rapt Therapeutics (RAPT) to Neutral from Overweight with a price target of $58, down from $95, after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GSK
Unlock Now
Guggenheim
Buy -> Neutral
downgrade
$58
2026-01-20
New
Reason
Guggenheim
Price Target
$58
2026-01-20
New
downgrade
Buy -> Neutral
Reason
Guggenheim downgraded Rapt Therapeutics (RAPT) to Neutral from Buy after GSK (GSK) announced an agreement to acquire Rapt for $58 per share in cash.
Deutsche Bank
Hold
to
Hold
upgrade
2026-01-16
Reason
Deutsche Bank
Price Target
2026-01-16
upgrade
Hold
to
Hold
Reason
Deutsche Bank raised the firm's price target on GSK to 1,675 GBp from 1,600 GBp and keeps a Hold rating on the shares.
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
